首页   >  
MAPK Pathway
  >  
MEK/ERK
  >   优立替尼
Ulixertinib 结构式

优立替尼

参考资料 仅供科学研究,不可用于个人用途。
货号 :BCP04232CAS号 :869886-67-9纯度:98%
全国免运费!免费咨询:400-099-8200 或 手机联系:13472751340
即时询价 ×

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • 基本信息与产品描述
CAS号 869886-67-9 货号 BCP04232
中文名 优立替尼
英文名 Ulixertinib
中文别名
英文别名 1956366-10-1; BVD-523; BVD 523; BVD523; VRT752271; VRT752271; VRT 752271;;
SMILES O=C(C1=CC(C2=CC(NC(C)C)=NC=C2Cl)=CN1)N[C@@H](C3=CC=CC(Cl)=C3)CO
化学名称
分子式 C21H22Cl2N4O2 分子量 433.33
纯度 98% 配送 惯例下常温包邮
产品描述 Ulixertinib, also known as BVD-523 and VRT752271, is an inhibitors of ERK protein kinase. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.
  • 技术资料和支持
在购买和使用瀚香生物产品的过程中,您遇到的任何问题,都可以咨询我们的免费热线:400-099-8200,或者和我们的客服 。 我们竭诚解决您的一切疑惑,保证您的舒心顺畅。

相关产品推荐

查看更多 >

Tags:Ulixertinib 供应商,Ulixertinib 购买,Ulixertinib 生产,Ulixertinib 批量,Ulixertinib 供应,Ulixertinib 订购,Ulixertinib 采购

2853530910